Skip to content

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01314508
Enrollment
0
Registered
2011-03-14
Start date
2011-06-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease, Growth Failure

Keywords

pre-pubertal children, pre-transplant, not treated with growth hormone for at least 3 months

Brief summary

A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver. Lack of response to growth hormone in people with chronic liver disease is characterized by high levels of growth hormone and low levels of growth factors. This growth hormone resistance is reflected in a variety of factors including insulin resistance and low nutritional intake. Unfortunately, growth hormone therapy has no effect for children with liver disease. In addition, failure of normal growth or malnutrition makes liver disease even worse in children, and growth hormone therapy is not likely to reverse this. A lack of proper nutrition is associated with hospitalizations and frequent complications. Poor growth is a predictor of poor outcomes after liver transplantation. Thus the management of children with liver disease remains a challenge. Children who have successful orthotopic liver transplants (OLT) show much improvement in some aspects of growth, including skin fold thickness, mid-arm circumference, and normalization of growth factor levels. However, some studies have recently reported that the growth of 15-20% of children remains poor even after a liver transplant. This can be explained by persistent abnormalities in growth factors after transplant. Growth factor was found to be a good tool for prognosis in patients with chronic liver disease. Studies showed that patients with liver cirrhosis and growth factor levels below normal values showed lower long-term survival rates compared with patients who had above normal values. This suggests that growth factor can be a good predictor of survival and early marker of poor liver function. In this case, aggressive feeding may modestly improve growth factor levels leading to improved growth but it is unlikely that effects will be optimal. The investigators propose that growth factor administration may have a positive effect that leads to better growth which is a major predictor of good outcome. To date, no reports study the use of growth factor in children with chronic liver disease. This study proposes to examine the effect of growth factor therapy in childhood chronic liver disease.

Interventions

Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Pre liver transplant patients with: * Chronic liver disease * Short stature (\< 5%) * Low IGF-1 (\<-1SDS for age) * Chronologic age 4-18 and bone age \< 14 for boys and \< 12 for girls (pre-pubertal)

Exclusion criteria

* Status post transplant * Evidence of malignancy * Diabetes mellitus * Participation in other clinical trials involving investigational products * Treatment with growth hormone within 3 months * Pregnancy * Significant abnormality in clinical results * Hypoglycemic at baseline * Allergic to benzyl alcohol

Design outcomes

Primary

MeasureTime frameDescription
Growth velocity is the primary outcome. Improved height SDSOne year of therapyImproved growth velocity with improved height standard deviation scores (SDS) is the primary expected result.

Secondary

MeasureTime frameDescription
Improved BMI12 monthsAn improved body mass index is a secondary expected result of this study.
Improved quality of life12 monthsAn improved quality of life as assessed by the Pediatric Quality of Life Inventory forms is another expected result.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026